sorafenib has been researched along with Blood Pressure, High in 67 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (23.88) | 29.6817 |
| 2010's | 45 (67.16) | 24.3611 |
| 2020's | 6 (8.96) | 2.80 |
| Authors | Studies |
|---|---|
| Armenian, S; Choo, S; Fradley, M; Guha, A; Kuo, D; Kutty, S; Ky, B; Leger, K; Narayan, HK; Sheline, K; Tremoulet, A; Wong, V; Yoon, J | 1 |
| Deshpande, H; Patwa, H; Peixoto, AJ; Wegner Wippel, C | 1 |
| Lee, JL; Lee, JY; Lee, N | 1 |
| Bottinor, WJ; Cella, D; DiPaola, RS; Flamand, Y; Haas, NB; Hundley, WG; Ky, B; ONeill, AM; Salsman, JM; Subramanian, P; Wagner, LI | 1 |
| Budolfsen, C; Bæk Møller, N; E Magnusson, N; Grimm, D; Infanger, M; Krüger, M; Wehland, M | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Wei, YJ; Yeh, ML; Yu, ML | 1 |
| Chuang, PH; Hsieh, MH; Hsieh, TH; Kao, CC; Kao, JT; Kao, TY; Lai, HC; Peng, CY | 1 |
| Ito, KI; Ito, Y; Kabu, K; Onoda, N; Sugitani, I; Takahashi, S; Tsukada, K; Yamaguchi, I | 1 |
| Baselga, J; Bergh, J; Bermejo, B; Chan, A; Costa, F; Gómez, HL; Gómez, P; Gradishar, WJ; Huang, L; Hudis, CA; Maeda, P; Mángel, L; Meinhardt, G; Melichar, B; Nagai, SE; Rapoport, BL; Roché, H; Schwartzberg, LS; Zamagni, C; Zhang, J | 1 |
| Fu, Y; Liang, J; Lin, L; Wei, X; Xu, W | 1 |
| Grønbæk, H; Køstner, AH; Ladekarl, M; Lassen, U; Olesen, RK; Sorensen, M | 1 |
| D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P | 1 |
| Hou, JN; Jiang, MD; Wang, Z; Weng, M; Wu, XL; Xu, GS; Xu, H; Zeng, WZ | 1 |
| Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H | 1 |
| Funakoshi, T; Galsky, MD; Latif, A | 1 |
| Audard, V; Bahleda, R; Baumelou, A; Bouachi, K; Bourry, E; Izzedine, H; Khayat, D; Lang, P; Mangier, M; Massard, C; Ollero, M; Ory, V; Pawlak, A; Péchoux, C; Sahali, D; Sendeyo, K; Soria, JC; Zhang, SY | 1 |
| Lee, YJ; Shin, SY | 1 |
| Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T | 1 |
| Brose, MS; Frenette, CT; Keefe, SM; Stein, SM | 1 |
| Grande, C; Walko, CM | 1 |
| Arruda, LS; Baum, M; Cisar, L; Kim, S; Motzer, RJ; Quinn, DI; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J; Wood, LS | 1 |
| Chen, J; Guo, H; Li, S; Li, Y; Liang, X; Meng, H; Shi, B; Zhang, D; Zhu, Y | 1 |
| Honda, M; Isobe, T; Komatsu, R; Kuramoto, S; Shindoh, H; Tabo, M | 1 |
| Adachi, T; Akutsu, N; Hamamoto, Y; Hirayama, D; Igarashi, M; Kaneto, H; Motoya, M; Sasaki, S; Shinomura, Y; Shitani, M; Takagi, H; Wakasugi, H; Yamamoto, H; Yawata, A; Yonezawa, K | 1 |
| Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Yang, Z | 1 |
| Beeram, M; Benjamin, D; Ketchum, N; Mahalingam, D; Malik, L; Michalek, J; Mita, A; Rodon, J; Sankhala, K; Sarantopoulos, J; Tolcher, A; Wright, J | 1 |
| Cainap, C; Carlson, DM; Chen, PJ; Cheng, Y; Chung, IJ; El-Nowiem, S; Eskens, FA; Gorbunova, V; Huang, WT; Kang, YK; Kudo, M; McKee, MD; Pan, H; Qian, J; Qin, S; Ricker, JL; Toh, HC | 1 |
| Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D | 1 |
| Ando, Y; Bonichon, F; Brose, MS; Chung, J; Fassnacht, M; Fugazzola, L; Gao, M; Hadjieva, T; Hasegawa, Y; Kappeler, C; Meinhardt, G; Park, DJ; Schlumberger, M; Shi, Y; Shong, YK; Smit, JW; Worden, F | 1 |
| Duprez, T; Filleul, B; Laruelle, M; Machiels, JP | 1 |
| Bisulli, M; Casadei Gardini, A; Cascinu, S; Corbelli, J; Donati, G; Faloppi, L; Foschi, FG; Frassineti, GL; Gardini, A; Giampalma, E; La Barba, G; Marisi, G; Scarpi, E; Scartozzi, M; Silvestris, N; Tamberi, S; Veneroni, L | 1 |
| Furuse, J; Ikeda, K; Inuyama, L; Ito, Y; Kaneko, S; Matsuzaki, Y; Minami, H; Okayama, Y; Okita, K; Sunaya, T | 1 |
| Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G | 1 |
| Aubert, RE; Clore, G; Epstein, RS; Herrera, V; Kourlas, H; La-Beck, NM; McLeod, HL; Walko, CM | 1 |
| Daher, IN; Yeh, ET | 1 |
| Paggi, S; Spinzi, G | 1 |
| Maitland, ML; Snider, KL | 1 |
| Jonkers, IJAM; van Buren, M | 1 |
| Ravaud, A; Sire, M | 1 |
| Billemont, B; Kelly, RJ; Rixe, O | 1 |
| Carbonell, CE; Coleman, TA; Davis, CH; Davis, WB; La Vine, DB | 1 |
| Black, HR; Elliott, WJ; Karrison, T; Kasza, KE; Maitland, ML; Moshier, K; Ratain, MJ; Sit, L; Stadler, WM; Undevia, SD | 1 |
| Atkins, MB; Humphreys, BD | 1 |
| Andreu, J; Carles, J; Serrano, C; Suárez, C | 1 |
| Addeo, R; Bianco, M; Capasso, E; Caraglia, M; Cennamo, G; D'Agostino, A; Faiola, V; Febbraro, A; Guarrasi, R; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Piai, G; Pisano, A; Prete, SD; Sabia, A; Savastano, C; Tarantino, L; Vincenzi, B | 1 |
| Chevreau, C; Dielenseger, P; Ederhy, S; Goldwasser, F; Grange, JD; Mortier, L; Neidhardt-Berard, ME; Robert, C; Rosmorduc, O; Scotté, F; Seitz, JF | 1 |
| Bellmunt, J; Eisen, T; Fishman, M; Quinn, D | 1 |
| Baum, CE; Dahut, WL; Danesi, R; English, BC; Figg, WD; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Liewehr, D; Price, DK; Sissung, TM; Venitz, J; Venzon, D; Yarchoan, R | 1 |
| Armstrong, C; Hull, D | 1 |
| Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Tod, M | 1 |
| Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L | 1 |
| Keresztes, RS; Wu, S | 1 |
| de Waal, R; Hulsbergen-van de Kaa, C; Kats-Ugurlu, G; Leenders, W; Maass, C; Mulders, P; Oosterwijk, E; van Herpen, C | 1 |
| Hye Khan, MA; Imig, JD; Nagasawa, T | 1 |
| Byrne, M; Estfan, B; Kim, R | 1 |
| Filipiak, KJ; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Waśko-Grabowska, A; Zaborowska, M; Żołnierek, J | 1 |
| Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Golmard, JL; Loriot, MA; Mir, O; Narjoz, C; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M | 1 |
| Banzato, A; Bertorelle, R; Ciccarino, P; Della Puppa, A; Denaro, L; Farina, P; Fiduccia, P; Gardiman, MP; Lombardi, G; Polo, V; Zagonel, V; Zustovich, F | 1 |
| Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ | 1 |
| Flaherty, KT; Gallagher, M; Mosenkis, A; O'Dwyer, PJ; Stevenson, JP; Townsend, RR; Veronese, ML | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L | 1 |
| Manchen, B; Wood, LS | 1 |
| Bonomi, L; Imarisio, I; Paglino, C; Porta, C | 1 |
| Chen, JJ; Kudelka, A; Lu, J; Wu, S; Zhu, X | 1 |
| Rini, BI | 1 |
| Demetri, GD; George, S; Humphreys, BD; Maki, RG; Morgan, JA; Patel, TV; Quigley, M | 1 |
16 review(s) available for sorafenib and Blood Pressure, High
| Article | Year |
|---|---|
Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
Topics: Axitinib; Carcinoma, Renal Cell; Humans; Hypertension; Kidney Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib; Sunitinib | 2019 |
Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Humans; Hypertension; Hypokinesia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Skin Diseases; Sorafenib; Survival | 2013 |
Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents; Blood Pressure; Chi-Square Distribution; Drug Administration Schedule; Humans; Hypertension; Incidence; Molecular Targeted Therapy; Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Severity of Illness Index; Sorafenib; Time Factors | 2013 |
Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Therapy; Humans; Hypertension; Incidence; Kidney Neoplasms; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Treatment Outcome | 2014 |
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib | 2015 |
Vascular complications of selected cancer therapies.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cisplatin; Fluorouracil; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Thrombosis; Vascular Diseases | 2008 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Renal toxicity of targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
[Use of sorafenib in patients with hepatocellular or renal carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Fatigue; Foot Dermatoses; Hand Dermatoses; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Experience with sorafenib and adverse event management.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypertension; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib | 2011 |
Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Blood Pressure; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2013 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
[Angiogenesis and renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2007 |
Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Drug Delivery Systems; Drug Eruptions; Drug Interactions; Drug Monitoring; Fatigue; Humans; Hypertension; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Compliance; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Risk Factors; Social Support; Sorafenib; Survival Rate; Treatment Outcome | 2007 |
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Benzenesulfonates; Erythema; Esophagitis; Exanthema; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Incidence; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk; Sorafenib | 2008 |
13 trial(s) available for sorafenib and Blood Pressure, High
| Article | Year |
|---|---|
Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805.
Topics: Adolescent; Cardiovascular Diseases; Female; Humans; Hypertension; Kidney Neoplasms; Retrospective Studies; Sorafenib; Stroke Volume; Sunitinib; Vascular Endothelial Growth Factor A; Ventricular Function, Left; Young Adult | 2023 |
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Neuroendocrine; Diarrhea; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Hypertension; Japan; Male; Neoplasm Grading; Niacinamide; Patient Dropouts; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms; Tumor Burden | 2017 |
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Hypertension; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Receptor, ErbB-2; Sorafenib; Taxoids; Treatment Outcome | 2017 |
Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Hypertension; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Axitinib; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proteinuria; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Disease Progression; Drug Monitoring; Early Termination of Clinical Trials; Feasibility Studies; Female; Hand-Foot Syndrome; Humans; Hypertension; Kinetics; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Sorafenib; Vascular Endothelial Growth Factors | 2014 |
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Dyspnea; Fatigue; Female; Humans; Hypertension; Hypocalcemia; Incidence; Iodine Radioisotopes; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Thyroid Neoplasms; Weight Loss | 2015 |
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Hand-Foot Syndrome; Humans; Hypertension; Immunohistochemistry; Male; Middle Aged; Myoepithelioma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-ret; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Salivary Gland Neoplasms; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2016 |
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Octreotide; Phenylurea Compounds; Pyridines; Sorafenib; Survival; Treatment Outcome | 2010 |
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Drug Eruptions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms | 2013 |
Mechanisms of hypertension associated with BAY 43-9006.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
38 other study(ies) available for sorafenib and Blood Pressure, High
| Article | Year |
|---|---|
Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration.
Topics: Antineoplastic Agents; Child; Heart Failure; Humans; Hypertension; Protein Kinase Inhibitors; Sorafenib; Tyrosine Kinase Inhibitors; United States; United States Food and Drug Administration | 2023 |
Neurogenic orthostatic hypotension after treatment with sorafenib.
Topics: Humans; Hypertension; Hypotension, Orthostatic; Male; Midodrine; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Sectional Studies; Humans; Hypertension; Kidney Neoplasms; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tyrosine Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2023 |
Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Comorbidity; Diabetes Mellitus; Female; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hypertension; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Obesity; Platelet Count; Prevalence; Prognosis; Proportional Hazards Models; Radiotherapy; Serum Albumin; Severity of Illness Index; Sorafenib; Survival Rate | 2020 |
Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypertension; Liver Neoplasms; Male; Metformin; Middle Aged; Prognosis; Retrospective Studies; Sorafenib; Taiwan | 2020 |
Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Sorafenib; Sunitinib | 2018 |
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug; Fibrosis; Hepatitis B; Hepatitis C; Humans; Hypertension; Italy; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Weight Loss | 2013 |
Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Animals; Base Sequence; Binding Sites; Biomarkers; Carrier Proteins; Case-Control Studies; Cell Line; Female; Gene Expression Regulation; Glomerulosclerosis, Focal Segmental; Humans; Hypertension; Kidney Diseases; Kidney Glomerulus; Male; Mice; Mice, Knockout; Middle Aged; Molecular Sequence Data; Nephrosis, Lipoid; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proteinuria; Renal Insufficiency; Sorafenib; Thrombotic Microangiopathies; Transcription Factor RelA; Transcription, Genetic; Transfection; Vascular Endothelial Growth Factors; Young Adult | 2014 |
Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib | 2013 |
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Exanthema; Female; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2014 |
Management of sorafenib-related adverse events: a clinician's perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Physicians; Sorafenib | 2014 |
Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Nurses; Patient Education as Topic; Pharmacists; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib | 2014 |
Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
Topics: Angiogenesis Inhibitors; Animals; Blood Pressure; Hypertension; Male; Niacinamide; Phenylurea Compounds; Quinazolines; Rats; Rats, Wistar; Risk; Signal Transduction; Sorafenib; Telemetry; Vascular Endothelial Growth Factor A | 2014 |
Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Retrospective Studies; Skin Diseases; Sorafenib | 2014 |
Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment.
Topics: Aged; Blood Pressure; Brain; Carcinoma, Renal Cell; Female; Humans; Hypertension; Immunosuppressive Agents; Kidney Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Neoplasm Recurrence, Local; Posterior Leukoencephalopathy Syndrome; Sorafenib; Thrombosis; Vascular Endothelial Growth Factor A | 2018 |
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Electrolytes; Female; Follow-Up Studies; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Child; Diarrhea; Disease Progression; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Hypertension; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Patient Acuity; Phenylurea Compounds; Product Surveillance, Postmarketing; Prospective Studies; Sex Factors; Sorafenib; Survival Rate; Withholding Treatment; Young Adult | 2016 |
Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.
Topics: Cohort Studies; Female; Humans; Hypertension; Hypothyroidism; Indoles; Male; Middle Aged; Niacinamide; Pharmacoepidemiology; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2017 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Hypertension; Incidence; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quality of Life; Sorafenib | 2008 |
Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
Topics: Angiogenesis Inhibitors; Antihypertensive Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Disease Progression; Glomerulonephritis, IGA; Humans; Hypertension; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Sorafenib; Transplantation, Homologous | 2009 |
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Pressure; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2010 |
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Cohort Studies; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
Rapid development of hypertension by sorafenib: toxicity or target?
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Pressure; Drug Delivery Systems; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension; Mice; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Acute aortic dissection during sorafenib-containing therapy.
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aortic Dissection; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; DNA, Neoplasm; Female; Foot Dermatoses; Genotype; Hand Dermatoses; Humans; Hypertension; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Continuity of Patient Care; Diarrhea; Drug Eruptions; Drug Monitoring; Female; Humans; Hypertension; Liver Neoplasms; Niacinamide; Nurse's Role; Oncology Nursing; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Safety; Sorafenib | 2010 |
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Calcium Channel Blockers; Carcinoma, Hepatocellular; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Felodipine; Humans; Hypertension; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diarrhea; Disease Progression; Follow-Up Studies; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Survival Rate | 2010 |
Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Coagulation Disorders; Carcinoma, Non-Small-Cell Lung; Humans; Hypertension; Indoles; Intestinal Perforation; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Vascular Endothelial Growth Factor A; Wound Healing | 2011 |
Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Depression; Female; Humans; Hypertension; Kidney Neoplasms; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.
Topics: Acute Kidney Injury; Animals; Benzenesulfonates; Captopril; Growth Inhibitors; Hypertension; Male; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Databases, Factual; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2013 |
Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Comorbidity; Disease-Free Survival; Female; Humans; Hypertension; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Sorafenib; Treatment Outcome | 2012 |
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Risk Factors; Skin; Sorafenib; UDP-Glucuronosyltransferase 1A9 | 2012 |
Quantifying hypertension in patients with cancer treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2008 |
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib | 2008 |